HDAC3 Inhibition to Restore CD8+ T Cell Effector Function
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing cancer treatments using CD8+ T cells, such as immunotherapies, face limitations in effectiveness due to tumor resistance and CD8+ T cell elimination or inactivation, necessitating improved methods to enhance T cell effector function.
Innovation Solution
Utilizing an antagonist of histone deacetylase 3 (HDAC3) to inhibit its activity in CD8+ T cells, either through small molecules like RGFP966 or CRISPR-Cas systems, to increase T cell effector function, potentially combined with other cancer therapies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If CD8+ T cell immunotherapies are used to treat cancer, then tumor regression is achieved, but tumor resistance and CD8+ T cell elimination/inactivation occur
Solution Approach 1:
The patent changes the epigenetic state of CD8+ T cells by inhibiting HDAC3 activity, which alters chromatin structure and gene expression. This parameter change in epigenetic regulation restores T cell effector functions and prevents tumor-induced inactivation, thereby maintaining T cell persistence and functionality while achieving tumor regression
Solution Approach 2:
The patent introduces HDAC3 inhibition as an intermediary mechanism between T cell activation and tumor killing. By targeting HDAC3 as a specific mediator, the patent overcomes tumor resistance mechanisms that would otherwise eliminate or inactivate T cells, thus resolving the contradiction between achieving tumor regression and maintaining T cell reliability
2Productivity
If HDAC3 activity is inhibited in CD8+ T cells, then T cell effector function is enhanced, but potential off-target effects on other HDAC enzymes may occur
Solution Approach 1:
The patent achieves local quality by developing HDAC3-selective inhibitors that specifically target HDAC3 activity in CD8+ T cells without significantly affecting other HDAC enzymes. This selectivity allows enhancement of T cell effector function while minimizing off-target effects, as the inhibitory action is localized to the specific enzyme and cell type needed for therapeutic effect
Solution Approach 2:
The patent segments the HDAC enzyme family targeting by focusing inhibition specifically on HDAC3 rather than all HDAC enzymes. This segmentation approach allows precise control over which enzyme activity is modified, thereby enhancing T cell function while avoiding harmful off-target effects on other HDAC enzymes that could have different biological consequences
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enhances CD8+ T cell activation and cytotoxicity, leading to improved tumor regression and increased antigen-specific immune response against cancers.
Implementation Method 1
contacting a T cell in the T cell population with a pharmaceutical composition comprising an antagonist of histone deacetylase 3 (HDAC3)... the antagonist reduces the activity of the HDAC3 protein in the T cell
Data Source
AI summary
Provided herein are novel methods for increasing T cell effector function in a T cell populations, as well as methods for increasing T cell effector function in a subject. The methods include contacting a T cell in a T cell population with a pharmaceutical composition comprising an antagonist of histone deacetylase 3 (HD) AC3). Also provided herein are methods for identifying a compound that modulates HDAC3 activity in cytotoxic T cells.